^
Association details:
| Biomarker: | SMARCB1 mutation + TMB-H |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Keytruda (pembrolizumab) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Clinical profile of SMARCA4/SMARCB1-mutated non-small cell lung carcinomas: A retrospective study in a Spanish institution
Published date:
03/23/2022
Excerpt:
ICB was administered in 12 patients with SMARCA4/B1-altered tumors (1st line pembrolizumab in monotherapy or in combination in 83% for metastatic disease). Median PFS for all immunotherapy-treated patients was 360 days(95%CI 158-562)….In our cohort, patients with genetic alterations in SMARCA4/SMARCB1 genes presented high TMB and prolonged responses to immunotherapy.
DOI:
https://doi.org/10.1016/j.annonc.2022.02.212
